Ask AI
ProCE Banner Activity

Expert Nursing Perspectives on EGFR-Targeted Therapy for NSCLC

Clinical Thought

This activity features expert nursing faculty insights from a recent live events series exploring contemporary use of EGFR-targeted therapy for NSCLC. 

Released: January 07, 2026

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC.

AstraZeneca

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Target Audience

This activity has been designed to meet the educational needs of nurse practitioners, oncology nurses, and other healthcare professionals who care for patients with non-small-cell lung cancer. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Explain practical testing for the early detection and identification of actionable EGFR mutations, including interpreting results and implications for treatment planning

  • Differentiate the mechanisms of action of tyrosine kinase inhibitors, bispecific antibodies, and other EGFR-targeted agents approved for EGFR-mutated NSCLC

  • Provide supportive care for patients receiving EGFR-targeted treatment for EGFR-mutated NSCLC, taking into account patient-specific considerations and emphasizing strategies to improve outcomes and quality of life

  • Identify and manage treatment-related AEs associated with EGFR-targeted therapies in patients with EGFR-mutated NSCLC, utilizing evidence-based strategies to minimize patient discomfort and optimize therapeutic outcomes

Disclosure

Primary Author

Beth Sandy, MSN, CRNP, FAPO: consultant/advisor/speaker: AbbVie, Amgen, AstraZeneca, Catalyst, Janssen, Jazz, Lilly, Merck, Pfizer.